Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.
Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; daily, for 42 d; female NCG mice with acute lymphoblastic leukemia (ALL) xenografts) has antineoplastic activity and inhibits tumor growth[1].
References:
[1]. Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.